SCN1A and Dravet syndrome: Also, a current approach using an antisense nucleotide directed against SCN1A-dsAS, which leads to an enhancement of SCN1A expression, shows some potential as a disease modifying concept for treatment of DS and awaits further clinical evaluation (Giagtzoglou 2021; Hsiao and others 2016).